• Benign Prostatic Hyperplasia
  • Hormone Therapy
  • Genomic Testing
  • Next-Generation Imaging
  • UTUC
  • OAB and Incontinence
  • Genitourinary Cancers
  • Kidney Cancer
  • Men's Health
  • Pediatrics
  • Female Urology
  • Sexual Dysfunction
  • Kidney Stones
  • Urologic Surgery
  • Bladder Cancer
  • Benign Conditions
  • Prostate Cancer

How a multidisciplinary approach resulted in salvage therapy for prostate cancer guideline

Opinion
Video

"Participating in AUA guidelines is really an exciting time," says Todd M. Morgan, MD.

In this video, Todd M. Morgan, MD, describes the process behind creating the AUA/ASTRO/SUO guideline for salvage therapy for prostate cancer, which was recently published in the Journal of Urology. Morgan is chief of urologic oncology, the Jack Lapides M.D. Research Professor and professor of urology at the University of Michigan, Ann Arbor.

Transcription:

Participating in AUA guidelines is really an exciting time. I've been able to participate in a few different guidelines, and this is the first one that I've had the opportunity to chair. A unique aspect of AUA guidelines is a robust methodological review. There's a team at OHSU led by Dr. Roger Chou, that starts with the questions that we as a committee think are important, and then they dive into the literature. They rate the levels of evidence. And it really extends in many ways beyond our normal clinical and scientific knowledge to a methodological approach that comes back to our entire team and says, okay, these are really the highest-level studies, these are maybe the second-tier and third-tier studies, and here are the evidence grades that could go with any of these given studies. That's a unique aspect of this. Another really important piece is that this is a joint guideline with the AUA but also ASTRO and then also the SUO. Using these organizations and their breadth and reach, we were able to assemble a real multidisciplinary panel. That meant members of the committee from radiation oncology, of course, also medical oncology, also nuclear medicine, also patient advocacy. It's an incredibly well-rounded group that can then tackle the questions from different angles. That's, I think, a key way that we get to such an important, well-thought-out, and well-constructed guideline.

This transcription was edited for clarity.

Related Videos
Michael S. Cookson, MD, MMHC, FACS, answers a question during a Zoom video interview
David Barquin, MD, answers a question during a Zoom video interview
Alexandra Tabakin, MD, answers a question during a Zoom video interview
Blurred interior of hospital |  Image Credit: © jakkapan - stock.adobe.com
Laura Bukavina, MD, MPH, answers a question during a Zoom video interview
Image of kidneys | Image Credit: © peterschreiber.media - stock.adobe.com
Related Content
© 2024 MJH Life Sciences

All rights reserved.